

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3864858

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	JAY C STRUM	05/09/2012
	FRANCIS X TAVARES	08/27/2012
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	G1 THERAPEUTICS, INC.	
<b>Street Address:</b>	450 WEST DRIVE	
<b>Internal Address:</b>	CB# 7295	
<b>City:</b>	CHAPEL HILL	
<b>State/Country:</b>	NORTH CAROLINA	
<b>Postal Code:</b>	27599-7295	
<b>PROPERTY NUMBERS Total: 1</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Patent Number:</b>	8598197	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	678-694-1262	
<b>Email:</b>	docket@kipsllc.com	
<b>Correspondent Name:</b>	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC	
<b>Address Line 1:</b>	400 PERIMETER CENTER TERRACE NE	
<b>Address Line 2:</b>	SUITE 200	
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30346	
<b>ATTORNEY DOCKET NUMBER:</b>	12024-008WO1US2	
<b>NAME OF SUBMITTER:</b>	BRENT R. BELLOWS	
<b>SIGNATURE:</b>	/Brent R. Bellows/	
<b>DATE SIGNED:</b>	05/09/2016	
<b>Total Attachments: 5</b>		
source=12024-008_ExecutedFamilyAssignment#page1.tif		
source=12024-008_ExecutedFamilyAssignment#page2.tif		
source=12024-008_ExecutedFamilyAssignment#page3.tif		

source=12024-008\_ExecutedFamilyAssignment#page4.tif

source=12024-008\_ExecutedFamilyAssignment#page5.tif

### ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to G-Zero Therapeutics, Inc., a Delaware corporation, having a place of business at 450 West Drive, CB # 7295, Chapel Hill, NC 27599-7295, ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- PCT Application No. PCT/US2011/057749, entitled "CDK Inhibitors," filed on October 25, 2011, which claims priority from a provisional application, filed on October 25, 2010, now bearing U.S. Application No. 61/406,498.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.


Title: CDK Inhibitors  
Filed: October 25, 2011  
Application No.: PCT/US2011/057749

---

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature

  
Jay C. Struth

Date of Signature

May 9, 2012

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, the person(s) named below (referred to as "INVENTOR" whether singular or plural) has sold, assigned, and transferred and does hereby sell, assign, and transfer to G-Zero Therapeutics, Inc., a Delaware corporation, having a place of business at 450 West Drive, CB # 7295, Chapel Hill, NC 27599-7295, ("ASSIGNEE"), for itself and its successors, transferees, and assignees, the following:

1. The entire worldwide right, title, and interest in all inventions and improvements ("SUBJECT MATTER") that are disclosed in the following provisional application filed under 35 U.S.C. § 111(b), non-provisional application filed under 35 U.S.C. § 111(a), international application filed according to the Patent Cooperation Treaty (PCT), or U.S. national phase application filed under 35 U.S.C. § 371 ("APPLICATION"):

- PCT Application No. PCT/US2011/057749, entitled "CDK Inhibitors," filed on October 25, 2011, which claims priority from a provisional application, filed on October 25, 2010, now bearing U.S. Application No. 61/406,498.

2. The entire worldwide right, title, and interest in and to:  
(a) the APPLICATION; (b) all applications claiming priority from the APPLICATION; (c) all provisional, utility, divisional, continuation, substitute, renewal, reissue, and other applications related thereto which have been or may be filed in the United States or elsewhere in the world; (d) all patents (including reissues and re-examinations) which may be granted on the applications set forth in (a), (b), and (c) above; and (e) all right of priority in the APPLICATION and in any underlying provisional or foreign application, together with all rights to recover damages for infringement of provisional rights.

INVENTOR agrees that ASSIGNEE may apply for and receive patents for SUBJECT MATTER in ASSIGNEE's own name.

INVENTOR agrees to do the following, when requested, and without further consideration, in order to carry out the intent of this Assignment: (1) execute all oaths, assignments, powers of attorney, applications, and other papers necessary or desirable to fully secure to ASSIGNEE the rights, titles and interests herein conveyed; (2) communicate to ASSIGNEE all known facts relating to the SUBJECT MATTER; and (3) generally do all lawful acts that ASSIGNEE shall consider desirable for securing, maintaining, and enforcing worldwide patent protection relating to the SUBJECT MATTER and for vesting in ASSIGNEE the rights, titles, and interests herein conveyed. INVENTOR further agrees to provide any successor, assign, or legal representative of ASSIGNEE with the benefits and assistance provided to ASSIGNEE hereunder.

INVENTOR represents that INVENTOR has the rights, titles, and interests to convey as set forth herein, and covenants with ASSIGNEE that the INVENTOR has not made and will not


Title: CDK Inhibitors  
Filed: October 25, 2011  
Application No.: PCT/US2011/057749


---

hereafter make any assignment, grant, mortgage, license, or other agreement affecting the rights, titles, and interests herein conveyed.

INVENTOR grants the attorney of record the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

This Assignment may be executed in one or more counterparts, each of which shall be deemed an original and all of which may be taken together as one and the same Assignment.

Name and Signature  
  
Francis X. Tavares

Date of Signature  
 , 2012

502320433 04/23/2013

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
G-Zero Therapeutics, Inc.	10/04/2012
RECEIVING PARTY DATA	
Name:	G1 Therapeutics, Inc.
Street Address:	450 West Drive CB# 7295
City:	Chapel Hill
State/Country:	NORTH CAROLINA
Postal Code:	27599-7295
PROPERTY NUMBERS Total: 1	
Property Type	Number
PCT Number:	US2011057749
CORRESPONDENCE DATA	
Fax Number:	6785917357
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	678-694-1442
Email:	kreb1@kipsllc.com
Correspondent Name:	Knowles IP Strategies
Address Line 1:	400 Perimeter Center Terrace NE
Address Line 2:	Suite 125
Address Line 4:	Atlanta, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	12024-008WO1 KLR ASSIGN
NAME OF SUBMITTER:	Kristi Rebel
Signature:	/Kristi Rebel/
Date:	04/23/2013
Total Attachments: 2 source=Change_of_name_G-Zero_to_G1#page2.tif source=Change_of_name_G-Zero_to_G1#page3.tif	

OP \$40.00 US2011057749

502320433

PATENT  
REEL: 030281 FRAME: 0893

RECORDED: 05/09/2016

PATENT  
REEL: 038521 FRAME: 0684